Carnoy P, Ravard S, Wemerman B, Soubrie P, Simon P
Pharmacol Biochem Behav. 1986 Sep;25(3):503-9. doi: 10.1016/0091-3057(86)90131-0.
In order to further assess the alterations (motor, motivational or cognitive) that might underlie animal behavioral deficits associated with a reduced dopamine transmission, the effects of apomorphine at doses thought to stimulate dopaminergic autoreceptors were studied on rat operant behavior. Apomorphine (30 micrograms/kg SC) decreased the number of food rewards obtained, when rats trained on a continuous reinforced schedule were shifted to schedules of fixed ratio higher than 2:FR3, FR4, and FR8. In rats shifted to a FR4 schedule, apomorphine (7.5, 15, 30, 60 micrograms/kg SC) dose-relatedly reduced the number of rewards obtained. In rats subjected to previous extinction sessions, apomorphine (30 micrograms/kg) did not affect lever pressing reinstated on presentation of primary reinforcers but inhibited responding renewed on presentation of secondary reinforcers. Under a FR(3 + 1) schedule where the last (rewarded) response was distinct from the initial (non-rewarded) responses, the detrimental effect of apomorphine on response rates was considerably weaker than under a conventional FR4 schedule. The reward deficits caused by apomorphine under the FR4 schedule were dose-dependently and completely reversed by amisulpride (0.125, 0.25, 0.5, 1 and 2 mg/kg), pimozide (0.125 mg/kg), sulpiride (8, 16, 32 and 64 mg/kg), but not by conventional neuroleptics (namely chlorpromazine, fluphenazine, haloperidol, metoclopramide and thioridazine). It is suggested that behavioral deficits associated with a reduced dopamine transmission such as that caused by low doses of apomorphine involve motivational and cognitive dysfunctions rather than motor impairments. In account of its differential sensitivity to neuroleptic drugs, apomorphine-induced deficit might have some relevance for a further delineation of the mechanisms of action of these compounds.
为了进一步评估可能是动物行为缺陷基础的改变(运动、动机或认知方面),这些缺陷与多巴胺传递减少相关,研究了阿扑吗啡在被认为可刺激多巴胺能自身受体的剂量下对大鼠操作性行为的影响。当在连续强化程序下训练的大鼠转换到固定比率高于2(FR3、FR4和FR8)的程序时,阿扑吗啡(30微克/千克,皮下注射)减少了获得的食物奖励数量。在转换到FR4程序的大鼠中,阿扑吗啡(7.5、15、30、60微克/千克,皮下注射)剂量依赖性地减少了获得的奖励数量。在经历过先前消退训练的大鼠中,阿扑吗啡(30微克/千克)不影响在呈现初级强化物时恢复的杠杆按压,但抑制在呈现次级强化物时重新出现的反应。在FR(3 + 1)程序下,其中最后一个(有奖励的)反应与最初的(无奖励的)反应不同,阿扑吗啡对反应率的有害影响比在传统的FR4程序下明显更弱。在FR4程序下阿扑吗啡引起的奖励缺陷被氨磺必利(0.125、0.25、0.5、1和2毫克/千克)、匹莫齐特(0.125毫克/千克)、舒必利(8、16、32和64毫克/千克)剂量依赖性地完全逆转,但传统抗精神病药物(即氯丙嗪、氟奋乃静、氟哌啶醇、甲氧氯普胺和硫利达嗪)则不能。提示与多巴胺传递减少相关的行为缺陷,如低剂量阿扑吗啡引起的缺陷,涉及动机和认知功能障碍而非运动损伤。鉴于其对抗精神病药物的不同敏感性,阿扑吗啡诱导的缺陷可能与进一步阐明这些化合物的作用机制有关。